A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.189)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective:To investigate the efficacy and safety of edaravone versus placebo in a more narrowly defined population of patients (Edaravone MCI-186-J19/NCT01492686), intended to replicate the findings of a previous post hoc analysis. Background:The efficacy of edaravone was previously evaluated in a randomized placebo controlled phase III study (Abe K et al. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 610-7). This study did not demonstrate efficacy versus placebo of edaravone as an investigative treatment for ALS, but hypothesis-driven post hoc analyses suggested an opportunity to demonstrate efficacy in a more narrowly defined patient population. Design/Methods: 137 patients were randomized 1:1 to receive edaravone or placebo following a 12-week pre-observation period. Selection criteria included: Definite or Probable ALS (El Escorial/revised Airlie House); Japan ALS severity classification grade<3; scoring≥2 points on each single ALSFRS-R item at screening; [percnt] forced vital capacity≥80[percnt]; and ALS duration≤2 years. Treatment consisted of 6 cycles of 60-mg edaravone/matching placebo treatment. Primary efficacy endpoint was change in ALS Functional Rating Scale-Revised (ALSFRS-R) score at week 24. Secondary endpoints included change in ALS Assessment Questionnaire (ALSAQ40) scores. Safety endpoints included adverse events (AEs) and laboratory tests. Results:Mean change (±SE) in ALSFRS-R score was -7.50±0.66 (placebo) and -5.01±0.64 (edaravone): a between group difference of 2.49±0.76 (P=0.001). Between group difference for ALSAQ40 was -8.79±4.03 (P=0.031). Both groups showed similar AE incidence (84.1[percnt] edaravone, 83.8[percnt] placebo). Incidence of serious AEs was 15.9[percnt] (edaravone) and 23.5[percnt] (placebo). The most common AEs were contusion, and dysphagia (16[percnt] and 13[percnt] of patients, respectively). Incidence of adverse drug reactions (ADRs) was 2.9[percnt] (edaravone) and 7.4[percnt] (placebo). There were no serious ADRs and no AEs that lead to death. Conclusion:Edaravone treated ALS patients meeting the protocol inclusion criteria had less functional loss at 6 months, and had less quality of life deterioration compared to those receiving standard of care.
Disclosure: Dr. Tanaka has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation. Dr. Sakata has received personal compensation for activities with the Mitsubishi Tanabe Pharmaceutical Corporation. Dr. Palumbo has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation. Dr. Akimoto has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation.
Monday, April 18 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.